These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30211623)

  • 1. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
    Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
    Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
    Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC
    Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
    Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP.
    Zare N; Haghjooy Javanmard S; Mehrzad V; Eskandari N; Kefayat A
    Leuk Lymphoma; 2019 Aug; 60(8):1877-1889. PubMed ID: 30714442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
    Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
    BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
    Song G; Song G; Ni H; Gu L; Liu H; Chen B; He B; Pan Y; Wang S; Cho WC
    Curr Cancer Drug Targets; 2014; 14(7):659-70. PubMed ID: 25146331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
    Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
    Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
    Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
    Meng Y; Quan L; Liu A
    Gene; 2018 Feb; 642():205-211. PubMed ID: 29128636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
    Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
    J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma.
    Xiao XB; Gu Y; Sun DL; Ding LY; Yuan XG; Jiang HW; Wu ZX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1620-1625. PubMed ID: 30840285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
    Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Ni H; Wang X; Liu H; Tian F; Song G
    Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
    Li J; Fu R; Yang L; Tu W
    Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The miRNA content of circulating exosomes in DLBCL patients and in vitro influence of DLBCL-derived exosomes on miRNA expression of healthy B-cells from peripheral blood.
    Caner V; Cetin GO; Hacioglu S; Baris IC; Tepeli E; Turk NS; Bagci G; Yararbas K; Cagliyan G
    Cancer Biomark; 2021; 32(4):519-529. PubMed ID: 34275894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.